Jpmorgan Chase & CO Adicet Bio, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,170 shares of ACET stock, worth $1,146. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,170
Previous 150,485
99.22%
Holding current value
$1,146
Previous $144,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding ACET
# of Institutions
54Shares Held
53.1MCall Options Held
27.2KPut Options Held
0-
Orbimed Advisors LLC San Diego, CA11.4MShares$11.2 Million0.25% of portfolio
-
Tang Capital Management LLC San Diego, CA8.22MShares$8.06 Million0.3% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.54MShares$7.39 Million0.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.75MShares$3.68 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$3.21 Million0.0% of portfolio
About Adicet Bio, Inc.
- Ticker ACET
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,030,800
- Market Cap $39.2M
- Description
- Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...